Navigation Links
Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
Date:12/20/2007

Funding Supports Phase 3 Program for Lead Product

MENLO PARK, Calif., Dec. 20 /PRNewswire/ -- Cogentus Pharmaceuticals Inc. announced today that it has completed a private placement financing, raising $62.5 million to support the clinical development of the company's novel antiplatelet therapy CGT-2168.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The Series C financing was led by the Keffi Group, with participation from Prospect Venture Partners, Ridgeback Capital, Apothecary Capital and Pinnacle Ventures. This represents the third round of equity financing for Cogentus, which is focused on developing novel combination medicines that significantly improve upon current treatment options in major therapeutic categories.

"Our experienced team has worked diligently to advance our lead development candidate, CGT-2168, and to initiate the global phase 3 clinical trial program that will be supported by these funds," said Cogentus President and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D. "Our goal for this program is to benefit patients by providing the next generation of safer antiplatelet medicines."

In addition, Jide Zeitlin, founder of the Keffi Group and former partner and global chief operating officer of investment banking of The Goldman Sachs Group, has been named to the Cogentus Board of Directors. He joins Donald Hayden, Jr., James Tananbaum, M.D., Robert Myers and Dr. Goldsmith on the board. Mr. Zeitlin also serves on the Board of Directors of Affiliated Managers Group, Coach, Inc. and is Chairman of the Board of Trustees of Amherst College.

"We are very pleased to welcome Jide onto our board," Dr. Goldsmith said. "His extensive experience in health care investment banking and his commercial relationships will add significant value as the company moves forward."

Cogentus has begun e
'/>"/>

SOURCE Cogentus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... May 30, 2015 Venus Viva has ... scars, large pores, deep wrinkles, stretch marks, pigmentation irregularities, ... professional, such as Dr. F. Victor Rueckl of Lakes ... clinical trials in Las Vegas. This body image solution ... a system that delivers proven results through a skin ...
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a new hanging ... signs ; making what was formerly an elite expensive ... points at a usual height of 16’-20’ are easily seen ... are very unique and more visible than the largest exhibits. ... labor and rigging the costs far outweigh the benefit of ...
(Date:5/29/2015)... MO (PRWEB) May 29, 2015 Based in ... autism awareness shirts for a couple of months ... Their latest release, which reads “I’m not misbehaving, I ... worn by the parent’s of an autistic child in order ... of autism. , Not only are they raising awareness through ...
(Date:5/29/2015)... 2015 What does community do? , ... community comes together to plant gardens, to teach young ... awareness of critical issues. Community invites everyone to help ... , "What Community Does" was commissioned by The Denver ... and released during the foundation’s Annual Celebration in May. ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the ... specialties, now offers The Smartest Rheumatologist . The ... disorders ranging from Fibromyalgia and Osteoporosis, to Arthritis and ... MDLinx, and Caroline Tredway, editorial head of The Smartest ... have on the physicians who participate. Says Tredway, “With ...
Breaking Medicine News(10 mins):Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:MDLinx Launches Smartest Rheumatologist 2
... testing a candidate 2009 H1N1 influenza vaccine in pregnant ... Allergy and Infectious Diseases (NIAID), part of the National ... higher risk of developing severe illness if they become ... they are strongly encouraged to receive the seasonal influenza ...
... , , , ... Islands announced that the National Science Foundation (NSF) recently honored ... NSF Faculty Early Career Development (CAREER) award. , ... recognition of Gillespie,s teaching and research in protein-ligand interactions and ...
... to staph infections, researchers say , WEDNESDAY, Sept. 9 ... properties, might kill MRSA bacteria. , A new study ... honey, made solely from flowers found on the New ... protein, which is needed for fatty acid biosynthesis. The ...
... Tysabri appears to awaken dormant, common virus that crosses over ... may have discovered part of the reason why Tysabri, a ... development of a rare but potentially deadly brain disease in ... dormant JC virus from its slumber, allowing it to cross ...
... WASHINGTON, Sept. 9 Statement of Lisa A. Rickard, ... reports from White House press secretary Robert Gibbs that President ... Congress: , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080919/USCHAMBERLOGO ... encouraged that President Obama understands the tremendous burden that medical ...
... , , HOFFMAN ESTATES, Ill., Sept. ... open tomorrow, Thursday, Sept. 10, and will continue through October 30, ... 900 Kmart Pharmacy locations for $25 while supplies last. ... your home for family health," says Robbert Ayshford, RPh, divisional vice ...
Cached Medicine News:Health News:NIAID launches 2009 H1N1 influenza vaccine trial in pregnant women 2Health News:CI Faculty Member Awarded Nearly $1 Million NSF Grant 2Health News:MRSA May Succumb to Honey 2Health News:Scientists Find Clue to Dangerous Side Effect of MS Drug 2Health News:Scientists Find Clue to Dangerous Side Effect of MS Drug 3Health News:U.S. Chamber Encourages Obama to Propose Meaningful Medical Liability Reforms in Speech to Congress 2Health News:Kmart Pharmacy Flu Clinics Begin September 10, 2009 2Health News:Kmart Pharmacy Flu Clinics Begin September 10, 2009 3
(Date:5/29/2015)... MENLO PARK, Calif. , May ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, presented ... of Cancer Research (AACR) Advances in Brain Cancer ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:5/29/2015)...  Eli Lilly and Company (NYSE: LLY ) ... they have entered into a clinical trial collaboration to ... anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ... medicine. The planned study will assess the combination as ... The Phase I study is expected to establish ...
(Date:5/29/2015)...  World-renowned prostate surgeon and New York Urologist, Dr. ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate ... at Lenox Hill Hospital is the only center using ... New York City . We,ve seen tremendous improvement in ... use of an MRI makes for a much more accurate ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... Nov. 14 The American Legion,welcomes the findings of ... scheduled to be released on Nov 14., "In ... on the health,of military personnel who have served in ... stress is timely and important," said Marty,Conatser, national commander ...
... Group, Inc.,(OTC Bulletin Board: ANPG), reported today ... the selection of its,disinfectant, EnviroTru(TM) for use ... EnviroTru(TM) is a multi-purpose disinfectant and ... meets EPA requirements for,Toxicity Category IV (no ...
Cached Medicine Technology:American Legion Anticipates Institute of Medicine Report on Gulf War Veterans 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3
... next generation of the ultra-quiet ... III retains all the smooth, ... a leading name for,aspiration surgery ... pumps for high powered operation, ...
Richardson Blade - for use with Bookler Universal Table Mounted Retractor Systems...
... term being used today to describe the nature of ... may have been used in silicone implants in the ... not new technology cohesive is simply a word ... nature of the gel. All of Mentor silicone gel-filled ...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
Medicine Products: